RNase Control Market Size, Share, and COVID-19 Impact Analysis, By Type (Human Origin RNase Inhibitor and Non-Human Origin RNase Inhibitor), By Technology (Next-Generation Sequencing (NGS), Reverse Transcription Polymerase Chain Reaction (RT-PCR), and Others), By End-user (Pharmaceuticals and Biotechnology Companies, Research and Academic Institutes, and Others), and Regional Forecast till 2032

RNA monitoring is a necessity while working with RNA samples in the laboratory. RNA is inherently weaker in structure than DNA; hence, obtaining full-length, high-quality RNA becomes challenging. Highly reactive hydroxyl groups are prone to bring enzymatic changes. Furthermore, RNA is more heat labile compared to DNA. RNase inhibitors inhibit a broad spectrum of RNases and prevent RNA degradation in applications such as cDNA synthesis, real-time reverse transcription polymerase chain reaction (RT-PCR), in vitro transcription/ translation reactions, RNA purification, and others. The above mentioned techniques are widely performed in genetic therapies, diagnostics, and other procedures in which these products are used in the prevention of RNase contamination. An increase in the number of patients suffering from genetic diseases such as sickle cell disease, cancer, Huntington's disease-like 2 (HDL2), the launch of innovative detection tests, and multiple genetic research initiatives are some of the major factors contributing to the growth of the RNase control market.

• According to a National Library of Medicine report published in February 2020, the epidemiological data determined that, out of 6,172 unique rare diseases, 71.9% were genetic. The Orphanet database collected this data. Such rising prevalence of genetic diseases increases the need for gene therapies and also emphasizes the need for gene-based research for which RNA monitoring is crucial.

However, less awareness among people about gene therapies and the extreme prices of such therapies limits the usage of the product in various techniques. Such factors are expected to hamper the market growth to a certain extent.

• For instance, in November 2021, according to a study performed by Frontiers Media S.A., pharmacists, physicians, and adults have limited knowledge about gene therapy. Such a situation can lead to a decline in the adoption of RNase inhibitors in emerging countries such as Saudi Arabia.

Impact of COVID-19 on the RNase Control Market

The COVID-19 pandemic had a slightly positive impact on the RNase control market due to the use of RNase control in detecting nucleic acids from SARS-CoV-2. The increase in hospital and diagnostic lab visits for testing purposes has led to the strong usage of these products. Furthermore, several government initiatives were adopted to decrease the price of RT-PCR tests in emerging countries which eventually increases the product usage. Such actions increased patient access to diagnostic tests. RNase inhibitors prevent RNA degradation in real-time PCR, which surged the RNase control market across the globe.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Key Genetic Diseases, By Key Countries, 2022


• Key Industry Developments


• Impact of COVID-19 on the RNase Control Market

Analysis by Type

Based on type, the human origin RNase inhibitor segment accounted for a significant proportion of the global RNase control market in 2022. Frequent launches in the human recombinant RNase inhibitor and its increasing use in research and treatments are prime factors driving the segmental growth.

• For instance, in September 2020, PCR Biosystems launched RiboShield RNase Inhibitor RNA-sensitive applications such as RNA purification, cDNA synthesis, RT-PCR, RNA sequencing, and in-situ hybridization.

Other factors contributing to the segment growth include increasing awareness about the personalized medicines and gene therapy, in which these products are usually used.

Regional Analysis

North America dominated the RNase control market in 2022 and is projected to maintain its position over the forecast period. The growth is mainly attributed to the robust growth of technology and increasing collaborations in the gene sector. These products are widely used in the sector as they prevent the degration or contamination of RNA. Additionally, rising levels of research and development and investments in the gene sector are driving the market growth in North America.

• For instance, in October 2021, the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), ten pharmaceutical companies, and five non-profit organizations collaborated to amplify gene therapies' research and development, benefiting around 30.0 million Americans.

Key Players Covered

The report includes the profiles of key players such as New England Biolabs, Promega Corporation, Integrated DNA Technologies, Inc., ACROBiosystems, Meridian, LGC Genomics Limited, VWR International, and LLC. Takara Bio Inc., Thermo Fisher Scientific Inc., TransGen Biotech Co., Ltd., and others.

Key Industry Developments

• In July 2023, Novo Nordisk partnered with Eleven Therapeutics to find new molecules that efficiently deliver RNA-based therapies. The collaboration was focused on cardiometabolic diseases.


• In July 2022, Kao Corporation launched a technique to store and transport Skin Surface Lipids-RNA (SSL-RNA) at ordinary temperature, maintaining its stability. It is used in Skin Surface Lipids-RNA Monitoring. This method is useful for the early detection and monitoring of atopic dermatitis (AD) in infants.


• In July 2020, Thermo Fisher Scientific Inc. launched TaqPath COVID-19 RNase P Combo Kit 2.0. It detects nucleic acids from SARS‑CoV‑2 and RNase P internal control in a single reaction well in nasopharyngeal and anterior or mid-turbinate nasal swabs.